1. Mechlorethamine, vincristine, melphalan and prednisone (MOMP) for the treatment of relapsed lymphoma in dogs.
- Author
-
Back AR, Schleis SE, Smrkovski OA, Lee J, Smith AN, and Phillips JC
- Subjects
- Animals, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Dog Diseases mortality, Dogs, Female, Lymphoma drug therapy, Lymphoma mortality, Lymphoma, B-Cell drug therapy, Lymphoma, B-Cell mortality, Lymphoma, B-Cell veterinary, Lymphoma, T-Cell drug therapy, Lymphoma, T-Cell mortality, Lymphoma, T-Cell veterinary, Male, Mechlorethamine therapeutic use, Melphalan therapeutic use, Prednisone therapeutic use, Recurrence, Survival Analysis, Vincristine therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Dog Diseases drug therapy, Lymphoma veterinary, Mechlorethamine administration & dosage, Melphalan administration & dosage, Prednisone administration & dosage, Vincristine administration & dosage
- Abstract
Eighty-eight dogs with relapsed lymphoma were treated with the MOMP (mechlorethamine, vincristine, melphalan and prednisone) protocol on a 28-day treatment cycle. The overall response rate (ORR) to the MOMP protocol was 51.1% for a median of 56 days (range 7-858 days). Twelve percent of dogs experienced a complete response for a median of 81 days (range 42-274 days) and 38.6% experienced a partial response for a median of 49 days (range 7-858 days). Dogs with T-cell lymphoma had an ORR of 55% for a median of 60 days (range 49-858 days) while those with B-cell lymphoma had an ORR of 57% for a median of 81 days (range 7-274 days) (P = 0.783). The overall survival time for all dogs was 183 days (range 17-974 days). Fifty-four percent of dogs experienced toxicity with the majority classified as grade I. The MOMP protocol seems well-tolerated and is an option for dogs with relapsed lymphoma., (© 2013 John Wiley & Sons Ltd.)
- Published
- 2015
- Full Text
- View/download PDF